Literature DB >> 24893535

Strengthening pharmacovigilance in South Africa.

U Mehta, M Dheda, G Steel, M Blockman, A Ntilivamunda, G Maartens, Y Pillay, K Cohen.   

Abstract

This report outlines findings and recommendations of a national pharmacovigilance workshop held in August 2012 in South Africa (SA). A survey of current pharmacovigilance activities, conducted in preparation for the meeting, identified multiple programmes collecting drug safety data in SA, with limited co-ordination at national level. The meeting resolved that existing pharmacovigilance programmes need to be strengthened and consolidated to ensure that important local safety issues are addressed, data can be pooled and compared and outputs shared more widely. Pharmacovigilance activities should inform treatment guidelines with the goal of improving patient care. A variety of pharmaco-epidemiological approaches should be employed, including nesting drug safety studies within existing sentinel cohorts and the creation of a pregnancy exposure registry. The attendees agreed on key principles that will inform a national pharmacovigilance plan and compiled a list of priority pharmacovigilance issues facing public health programmes in SA.

Entities:  

Mesh:

Year:  2014        PMID: 24893535     DOI: 10.7196/samj.7517

Source DB:  PubMed          Journal:  S Afr Med J


  9 in total

1.  Discordance between patient and clinician reports of adverse reactions to MDR-TB treatment.

Authors:  A M Kelly; B Smith; Z Luo; B Given; T Wehrwein; I Master; J E Farley
Journal:  Int J Tuberc Lung Dis       Date:  2016-04       Impact factor: 2.373

2.  Pharmacovigilance: A public health priority for South Africa.

Authors:  Ushma Mehta; Emma Kalk; Andrew Boulle; Portia Nkambule; Joey Gouws; Helen Rees; Karen Cohen
Journal:  S Afr Health Rev       Date:  2017-08-23

3.  Assessment of Knowledge, Attitude and Practice of Adverse Drug Reaction Reporting Among Healthcare Professionals working in Primary, Secondary and Tertiary Healthcare Facilities in Ekiti State, South-West Nigeria.

Authors:  Theophilus A Adegbuyi; Joseph O Fadare; Ebisola J Araromi; Abayomi O Sijuade; Iyanu Bankole; Ilesanmi K Fasuba; Rachel A Alabi
Journal:  Hosp Pharm       Date:  2020-09-18

4.  Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.

Authors:  Kathryn Schnippel; Rebecca H Berhanu; Andrew Black; Cynthia Firnhaber; Norah Maitisa; Denise Evans; Edina Sinanovic
Journal:  BMC Infect Dis       Date:  2016-10-21       Impact factor: 3.090

5.  Ongoing Initiatives to Improve the Quality and Efficiency of Medicine Use within the Public Healthcare System in South Africa; A Preliminary Study.

Authors:  Johanna C Meyer; Natalie Schellack; Jacobus Stokes; Ruth Lancaster; Helecine Zeeman; Douglas Defty; Brian Godman; Gavin Steel
Journal:  Front Pharmacol       Date:  2017-11-09       Impact factor: 5.810

6.  Adult medical emergency unit presentations due to adverse drug reactions in a setting of high HIV prevalence.

Authors:  Johannes P Mouton; Nicole Jobanputra; Christine Njuguna; Hannah Gunter; Annemie Stewart; Ushma Mehta; Sa'ad Lahri; Richard Court; Ehimario Igumbor; Gary Maartens; Karen Cohen
Journal:  Afr J Emerg Med       Date:  2020-11-30

7.  Perceptions, practices and barriers to reporting of adverse drug reactions among HIV infected patients and their doctors in 3 public sector hospitals of the Ethekwini Metropolitan, Kwa-Zulu Natal: a cross sectional and retrospective analysis.

Authors:  Sindiswa Zondi; Panjasaram Naidoo
Journal:  BMC Health Serv Res       Date:  2022-08-18       Impact factor: 2.908

8.  Pharmacovigilance of suspected or confirmed therapeutic ineffectiveness of artemisinin-based combination therapy: extent, associated factors, challenges and solutions to reporting.

Authors:  Ronald Kiguba; Helen Byomire Ndagije; Victoria Nambasa; Leonard Manirakiza; Elijah Kirabira; Allan Serwanga; Sten Olsson; Niko Speybroeck; Jackson Mukonzo
Journal:  Malar J       Date:  2020-11-03       Impact factor: 2.979

Review 9.  Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India.

Authors:  Jai Prakash; Raghav Sachdeva; Tarani Prakash Shrivastava; C V Jayachandran; Aseem Sahu
Journal:  Indian J Pharmacol       Date:  2021 Mar-Apr       Impact factor: 1.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.